Skip to main content

Advertisement

SpringerLink
Log in

Relevanz stereotaktischer ablativer Strahlentherapie bei systemisch metastasierten Patienten

Relevance of stereotactic ablative radiotherapy in patients with systemic metastasis

  • Literatur kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Palma DA, Olson R, Harrow S et al (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 393:2051–2058

    Article  Google Scholar 

  2. Pitroda SP, Weichselbaum RR (2019) Integrated molecular and clinical staging defines the spectrum of metastatic cancer. Nat Rev Clin Oncol. https://doi.org/10.1038/s41571-019-0220-6

    Article  PubMed  Google Scholar 

  3. Winkelmann MT, Clasen S, Pereira PL, Hoffmann R (2019) Local treatment of oligometastatic disease: current role. Br J Radiol:20180835. https://doi.org/10.1259/bjr.20180835

    Article  PubMed  Google Scholar 

  4. Gomez DR, Tang C, Zhang J et al (2019) Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: Long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol 37:1558–1565

    Article  Google Scholar 

  5. Hoerner-Rieber J, Duma M, Blanck O et al (2017) Stereotactic body radiotherapy (SBRT) for pulmonary metastases from renal cell carcinoma—a multicenter analysis of the German working group “Stereotactic Radiotherapy”. J Thorac Dis 9:4512–4522

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Oncology and Palliative Medicine, Nordland Hospital Trust, P.O. Box 1480, 8092, Bodø, Norwegen

    Carsten Nieder

Authors
  1. Carsten Nieder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carsten Nieder.

Ethics declarations

Interessenkonflikt

C. Nieder gibt an, dass kein Interessenkonflikt besteht.

Additional information

Originalpublikation

Palma DA, Olson R, Harrow S et al (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 393:2051–2058

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nieder, C. Relevanz stereotaktischer ablativer Strahlentherapie bei systemisch metastasierten Patienten. Strahlenther Onkol 195, 943–944 (2019). https://doi.org/10.1007/s00066-019-01505-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-019-01505-x

Search

Navigation